About Ixchelsis
Ixchelsis was a Healthcare company based in Sandwich (United Kingdom) founded in 2011. It develops oxytocin receptor antagonists for treating genitourinary disorders. It operates on a B2B model. Ixchelsis has raised $26 million across 2 funding rounds from investors including Pfizer Venture Investments and TVM Capital Life Science. The company has 4 employees. The company is recorded as dissolved. Its focus areas include Pharmaceuticals, Drug Development and Therapeutics. Its legal entity is IXCHELSIS LIMITED. Its competitors include Lipella, TheraVida, Esprit Pharma, Regenfro Co and Kissei Pharmaceutical and 4 more; 7 of its 9 listed competitors have raised funding.
Company details
Ixchelsis, backed by 26000000.0 from Pfizer Venture Investments, TVM Capital, focuses on providing healthcare solutions, producing pharmaceutical products, drug development, and therapeutics. Develops oxytocin receptor antagonists for treating genitourinary disorders. Driving innovation, growth, and excellence in its industry sectors. It continues to evolve, meeting industry challenges with strategic approaches.
- Headquarters Sandwich, United Kingdom
- Employees 4
- SectorsHealthcare
- Website ixchelsis.com
- Legal Name Ixchelsis Limited
- Date of Incorporation 27 Jul, 2011
- Jurisdiction SEVENOAKS, ENGLAND
- Total Equity Funding$26M (USD)
in 2 rounds
- Latest Funding Round$12M (USD), Series A
Dec 2016
- InvestorsPfizer Venture Investments
& 1 more
- Employee Count4
Funding Insights of Ixchelsis
Ixchelsis has successfully raised a total of $26M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $12 million completed in December 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $26M
- Total Rounds 2
- Last Round Series A — $12M
- First Round $14M
(Aug 2013)
- Investors Count 2
All 2 funding rounds of Ixchelsis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2016 | $12M | Series A | – | – | |
| Aug 2013 | $14M | Series A | – | TVM Capital | – |
2 investors in total: 2 institutional.
Investors in Ixchelsis
Ixchelsis has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Pfizer Venture Investments and TVM Capital Life Science.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital is focused on healthcare by Pfizer's investment arm. | – | pfizer.com/partnering/areas_of_interest/venture_investments | New York, United States | |
Capital is invested in life science innovations for healthcare transformation. | – | tvm-capital.com | Munich, Germany |
Investor details for Ixchelsis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Ixchelsis
3 dated milestones of Ixchelsis across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Ixchelsis is founded.
- Funding First funding round of $14.0M.
- Funding Latest funding round, Series A, of $12.0M.
Competitors of Ixchelsis
Ixchelsis has 9 listed competitors in our database, 7 of them funded. They include Lipella, TheraVida, Esprit Pharma, Regenfro Co and Kissei Pharmaceutical, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lipella.com | 2005 | Pittsburgh, United States | $3.37M | 5 | Lipid-based therapies for common bladder syndromes are developed. | |
| theravida.com | 2005 | San Mateo, United States | $12.5M | – | Clinical stage biopharma company developing drugs for urology and central nervous system disorders | |
| espritpharma.com | 2005 | East Brunswick, United States | $219.49M | – | Develop drugs for genitourinary (GU) disorders | |
| regenephro.co.jp | 2019 | Kyoto, Japan | $28.88M | – | Developer of therapeutics to treat renal diseases | |
| kissei.co.jp | 1946 | Matsumoto, Japan | – | – | Therapies for renal diseases and urology-related anemia are developed. | |
| aceruspharma.com | 2008 | Mississauga, Canada | $38.07M | – | Develops pharmaceuticals for urology, hormone replacement therapy, and female sexual dysfunction treatments. | |
| urovant.com | 2017 | Irvine, United States | – | – | Therapies for urological disorders such as overactive bladder are developed. | |
| urigen.com | 1997 | North Brunswick, United States | $3.02M | – | Pain relief products for urological ailments are developed and tested. | |
| ixaltis.com | 2012 | Toulouse, France | $8.89M | – | Therapeutics for genito-urinary diseases including stress urinary incontinence are developed. |
Detailed competitors of Ixchelsis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
10 companies that operate in the same segment as Ixchelsis (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ixchelsis
Complete news archive for Ixchelsis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ixchelsis
Ixchelsis was founded in 2011 and raised its 1st funding round 2 years after it was founded.
Ixchelsis is headquartered in Sandwich, United Kingdom.
Ixchelsis is a funded company, having raised a total of $26M across 2 funding rounds to date. The company's 1st funding round was a Series A of $14M, raised on Aug 2013.
Ixchelsis has 4 employees.
Ixchelsis, backed by 26000000.0 from Pfizer Venture Investments, TVM Capital, focuses on providing healthcare solutions, producing pharmaceutical products, drug development, and therapeutics. Develops oxytocin receptor antagonists for treating genitourinary disorders. Driving innovation, growth, and excellence in its industry sectors. It continues to evolve, meeting industry challenges with strategic approaches.
Ixchelsis's top competitors include Lipella, Kissei Pharmaceutical and Regenfro Co.
Ixchelsis has 2 investors. Key investors include Pfizer Venture Investments, and TVM Capital Life Science.
Ixchelsis operates through Ixchelsis Limited.